# This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

> **NCT03156114** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 172 (actual)

## Conditions studied

- Neoplasms
- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Ezabenlimab
- **DRUG:** BI 754111

## Key facts

- **NCT ID:** NCT03156114
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-13
- **Primary completion:** 2023-03-09
- **Final completion:** 2023-06-06
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03156114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03156114, "This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03156114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*